The severe combined immunodeficiency (SCID) mouse was investigated as a model system to study the growth and immunogenicity of human gliomas. Human glioma cell lines U-251MG, KNS-42, SF-188, A-172, and T-98G were injected subcutaneously into SCID mice. The cell lines U-251MG and KNS-42 grew as large, subcutaneous masses; SF-188, A-172, and T-98G did not grow. Glioma-immune system interactions were studied by the transplantation of human peripheral blood lymphocytes into tumor bearing SCID mice. In the resultant SCID-human (SCID-hu) mice, transplanted lymphocytes infiltrat ed into the subcutaneously growing tumors and expressed the surface markers of human B, T, and natural killer cells. The SCID-hu mouse is a potentially powerful model to study the basic tumor biolo gy of some human gliomas and also represents a useful screening system to evaluate experimental im munotherapies for brain tumors.
Introduction
The development of animal models of human glioma and other tumors is necessary to study tumor growth, pathogenesis, and response to experimental therapies. There are two types of transplant models: syngeneic tumors induced by viruses or chemicals, and heterotransplantation models in which a tumor from another species is transplanted into either an im munoincompetent recipient or an immunologically privileged site. Heterologous transplantation of hu man brain tumors was essentially unsuccessful until the development of the nude mouse, a mutant that is genetically thymus-deficient and therefore im munocompromised.2,1,6,22,36,37,39,44,41,48) However, since nude mice have residual natural killer (NK) activity and antibody-dependent cell-mediated cytotoxicity activity, the growth of many tumors is limited.
The severe combined immunodeficiency (SCID) mouse provides a better model system for some neo plasms.4,16,17) Human gastric cancer and ovarian can cer grow significantly better in SCID mice than in nude mice.") Leukemic cells and lymphoma cells, which do not proliferate in nude mice, grow well in SCID mice.21,43) In addition, melanoma and germ cell tumors metastasize in SCID mice. 16,35 SCID mice lack both B and T cell-mediated immunity due to a gene rearrangement defect. 11,11,46,47) The deoxy ribonucleic acid-dependent kinase (p350) has been identified recently as a candidate gene for the mouse SCID defect.23) Since the only preserved immune functions in the SCID mouse are antigen presenta tion by macrophages and NK cell activity, these animals are more immunocompromised than nude mice. 10-12) Transplanted tumors tend to grow more ag gressively and may have the capacity to metasta size. 16, 17) A second advantage of the SCID mouse is that transplantation of human thymi, liver, and lymph nodes or of human adult peripheral blood lympho cytes (PBLs) reconstitutes a partial immune func tion. 29,30> The resultant SCID-human (SCID-hu) mice have a transient wave of human CD4 and C138-posi tive T cells and human immunoglobulins (Ig) in the peripheral circulation. These animals are an ideal model system to study human tumor-immune system interactions. Prior work in another laboratory has demonstrated the feasibility of growing human glio mas in SCID mice.49 '50 The present study attempted to establish the SCID-hu mouse as an in vivo system to examine hu man glioma immunoreactivity.
Materials
and Methods
I. Mice
Five-week-old male CB-17 SCID mice and im munocompetent CB-17 mice were purchased from Clea Japan, Inc., Tokyo. They were maintained un der specific pathogen-free conditions using a clean rack, and fed on sterile food and water ad libitum in our experimental animal center. Care was in accor dance with institutional guidelines. Six to 10-week old male mice weighing 20-30 g were used for the ex periments.
II. Human tumor cell lines
Human glioma cell lines (U-251MG, KNS-42, T 98G, SF-188, and A-172) were maintained in RPMI 1640 medium supplemented with 10% fetal bovine se rum (FBS) and kanamycin sulfate (50 mg/ml), and grown in monolayer culture at 37°C in a humidified chamber under a 5% CO2 and 95% air atmosphere. KNS-42 was kindly supplied by T. Takeshita (Kyushu University, Kyushu) and SF-188 by T. Aida (Hokkaido University, Sapporo). Other cell lines were obtained from the Japanese Cancer Research Resources Bank (Tokyo).
III. Tumor implantation
Semiconfluent cells were treated with 0.05% ethylenediaminetetra-acetic acid for 10 minutes at 37°C to obtain single cells and then washed with growth medium. Approximately 2 x 10' cells were resuspended with 200 ul of growth medium and were inoculated subcutaneously into the flank of SCID mice under ether anesthesia.
IV. SCID-hu system
Heparinized venous blood from a human healthy volunteer was separated on a Ficoll-Hypaque gradient (Nakalai Tesque, Inc., Kyoto). After cen trifugation at 400g for 30 minutes, the lymphocyte layer was collected, washed three times with phos phate buffered saline solution (PBS), suspended in RPMI-1640 with 10% FBS, and adjusted to 2.0 X 10' lymphocytes/ml. Under ether anesthesia, 1.0 x 10' PBLs mixed with 20,ul of anti-asialo GM1 an tibody (WAKO Chemical Industries, Ltd., Osaka) were injected into the peritoneal cavity of both tumor-bearing and control SCID mice.
V. Measurement of human IgG
At 1, 3, 4, and 5 weeks after inoculation of PBLs, blood was collected from the postocular vessels, and the serum concentration of human IgG was mea sured by an enzyme-linked immunosorbent assay (ELISA). 96-well plates were coated with 5µg/ml of anti-human IgG (DAKO Co. Ltd., Copenhagen, Denmark) overnight at 4°C. After washing with PBS, wells were treated with PBS containing 1 % bo vine serum albumin (BSA) for 60 minutes at room temperature. The serum sample or serially diluted standard human IgG was added. After incubation and washing, peroxidase-conjugated rabbit anti-hu man IgG (DAKO Co. Ltd.) was added, and the rela tive amounts of bound enzyme conjugate in the wells were ascertained by addition of o-phenylenediamine. The extent of hydrolysis was measured at 495 nm in an EIA Reader (Model 2550; BIO-RAD, Tokyo). Se rum IgG concentrations were calculated from the standard curve.
VI. Immunoperoxidase staining
Tumor and spleen specimens were fixed with 10% buffered formalin and embedded in paraffin. Paraffin-embedded sections (6,um) were deparaffin ized with xylene and rehydrated with a graded ethanol and PBS series. Sections were preincubated with 0.03% H2O2 in methanol for 20 minutes and washed with PBS for 20 minutes. Sections were in cubated with normal goat serum in PBS for 30 min utes, then monoclonal CD45RO antibody (DAKO Co. Ltd.), monoclonal CD20 antibody (DAKO Co. Ltd.), or polyclonal CD56 antibody (Affinity Re search Products Ltd., Ilkeston, U.K.) for 30 minutes. After washing with PBS for 20 minutes, sections were incubated with biotinylated goat anti-mouse IgG (DAKO Co. Ltd.) or anti-rabbit IgG (DAKO Co. Ltd.) for 30 minutes. After PBS washing for 20 minutes, sections were incubated with an avidin biotin-peroxidase complex for 30 minutes. After PBS washing, the peroxidase reaction was initiated with 0.06% diaminobenzidine and 0.01% H202 in 50 mM Tris-HC1 (pH 7.0) for 5 minutes. Nuclei were briefly counterstained with Meyer's hematoxylin. Negative control sections were incubated with PBS contain ing 3% BSA instead of the primary antibodies.
VII. Flow cytometry
A spleen was minced with scissors into about four pieces in PBS. Spleen cells were pushed out gently from the minced spleen with forceps and passed through a nylon mesh. The spleen cells were then washed with PBS con taining 1% BSA and 0.05% sodium azide. The cells were incubated for 30 minutes at 4°C with CD4 (DAKO Co. Ltd.), CD8 (DAKO Co. Ltd.), CD19 (DAKO Co. Ltd.), or CD56 (MONOSAN, Uden, the Netherlands) antibody. After washing with PBS con taining 1% BSA and 0.05% sodium azide, cells were stained with a 1:20 dilution of fluorescein isothio cyanate (FITC)-labeled goat anti-mouse IgG for 30 minutes at 4°C. After washing, the FITC signal was measured with a fluorescein-activated cell sorter (FACScan; Becton-Dickinson Inc., Mountain View, Cal., U.S.A.). Cells incubated with PBS containing 3% BSA instead of primary antibodies were used as controls.
Results

I. Tumor implantation into SCID mice
Malignant glioma cell lines, U-251MG, KNS-42, A-172, SF-188, or T-98G, were implanted into SCID mice. Implanted A-172 (n = 3), SF-188 (n = 3), or T-98G (n = 3) cells did not grow subcutaneously in SCID mice. U-251MG (n = 8) and KNS-42 (n = 6) cells formed large local tumors in all SCID mice. The tumor growth of U-251MG was confirmed histologi cally about 2-3 months after transplantation of glio ma cells, and growth of KNS-42 about 1-2 months later. Macroscopically, tumors did not invade into the surrounding tissue, and no evidence of metastasis to any organs was found (Fig. 1 ).
II. SCID-hu system
Human PBLs were prepared and injected in traperitoneally with 20,ul anti-asialo GM I antibody into SCID mice. One month after implantation, the spleens of SCID mice were hypertrophic macroscop ically compared to those of unimplanted SCID mice. Microscopy demonstrated many lymphocytes in HE-stained sections of the spleens of tumor bearing SCID-hu mice (Fig. 2B ). In contrast, spleens of control SCID mice had no significant lymphocytic staining ( Fig. 2A) . Immunoperoxidase staining showed some lymphocytes in the spleen were positive for the human lymphocyte cell surface markers CD20 (Fig. 3A) , CD45RO (Fig. 3B ), and CD56 (Fig. 3C ). Flow cytometric analysis showed that 10% of lymphocytes in the spleens of implant ed SCID mice were human CD4-positive cells, 10% CD8-positive cells, and 30% C1319-positive cells (Fig. 4) . Mononuclear cells in the spleens of control SCID mice did not express the cell surface markers of human lymphocytes (data not shown). Human IgG was detected in the serum of SCID-hu mice by ELISA. Production of human IgG was maximum at 3 weeks after human PBL transplantation (Table  1) . showing indirect immunoperoxidase staining of the specimen from SCID-hu mouse spleen using specific antibodies to the human lymphocyte markers CD20 (A), CD45RO (B), and CD56 (C), with specific staining for all three markers.
Immunoperoxidase stain, x 200. III. Analysis of tumor-infiltrating lymphocytes (TILs) Microscopy showed proliferation of spindle and oval-shaped glioma cells with central necrosis in the SCID mice transplanted with U-251MG. Although few TILs were found in the U-251MG tumors of mice without inoculation of human PBLs, many lym phocytes had infiltrated into the tumors of SCID-hu mice (Fig. 5A) . Immunoperoxidase staining showed CD45RO-positive cells in many fields (Fig. 6B ), C1320-positive cells in some fields (Fig. 6A) , and CD56-positive cells in peripheral areas of tumor tis sues (Fig. 6C) .
KNS-42 tumors also demonstrated growth of spin dle-like cells and lymphocyte infiltration (Fig. 5B) . However, the degree of lymphocyte infiltration into KNS-42 tumors was less than into U-251MG tumors. Immunoperoxidase staining revealed that CD45RO positive cells (Fig. 6E) had infiltrated in the marginal area of tumor necrosis but not CD20 (Fig. 6D) or CD56 (Fig. 6F) 
Discussion
The present study shows that the human glioma cell lines U-251MG and KNS-42, but not SF-188, A-172, or T-98G, can grow as solitary subcutaneous masses in SCID mice; SCID-hu mice can be generated by transplantation of human PBLs; and that these SCID-hu mice demonstrate significant tumor lym phocyte invasion.
I. Tumor implantation Nude mice have been used for many years to grow various human tumors, but we expected that SCID mice would be better recipients for growth of human tumors because the immune deficiency in SCID mice is more severe than in nude mice.2,s,6,22,36,37,39,44,as,aa) The feasibility of using the SCID mouse model to study human glioma has been shown by the success ful transplantation of human and murine brain tumors into the subcutaneous tissue and brain of SCID mice.49,50) Our study implanted five human brain tumor cell lines into the subcutaneous tissue of SCID mice. Two of the cell lines, U-251MG and KNS-42, grew but the other three cell lines did not, suggesting that the success of xenografts in SCID mice may be dependent on tumor cell immunogenici ty. Although SCID mice are immunocompromised, NK activity and antigen-presenting function are nor mal. 10-12) Hill et al. 17) have reported significant an titumor activity of human NK cells against human melanoma xenografts in SCID mice and augmenta tion by interleukin-2, alone or in combination with interleukin-12.
Likewise, most human glioma cell lines are susceptible to NK cell lysis.3,19,20,31,41,42) The degree of susceptibility is multifactorial and depends on the period in culture and on secretion of im munosuppressants such as transforming growth fac tor-,62 and prostaglandin E2.26,34 Further investiga tion is necessary to elucidate the complex interac tions between NK cells and gliomas.
II. SCID-hu system
Normal human hematopoietic cells were difficult to maintain in vivo until the introduction of SCID mice. McCune et a1.30) produced SCID-hu mice by the grafting of human fetal liver, thymus, and lymph node into SCID mice. Human mature B and T cells were identified in the SCID-hu mouse peripheral cir culation, and human Ig were produced.2s,30 However, the reconstitution of T cell surface mark ers was incomplete. In addition, SCID mice receiv ing transplanted human bone marrow and subse quently treatment with human cytokines demonstrat ed repopulation of the mouse bone marrow with im mature human cells and differentiation of those cells to multiple myeloid and lymphoid lineages .21,13) in our study, we implanted normal human PBLs from healthy donors.
Human PBLs injected in traperitoneally migrated and survived in the SCID mouse spleen, showing that a lymphocytic homing phenomenon occurs in SCID mice. We also showed that human IgG is produced in the SCID mouse peripheral circulation. These results are consistent with previous studies that have shown antigen specific Ig synthesis in SCID-hu mice. 15) SCID-hu mice can also generate specific T cell-mediated im munity, 29) although not demonstrated in the present study. Our results further confirm that the SCID-hu model is useful as a reconstitution model of the hu man immune system.
III. Analysis of TILs
The current view that the brain is not necessarily an immunologically privileged site is based partly on evidence that mononuclear cells can infiltrate the parenchyma of malignant gliomas.31,13) The presence of TILs within gliomas is considered to be a favor able prognostic sign, and possibly indicative of a host immune response against the tumor. TILs isolated from gliomas generally consist predomi nantly of C138-positive cytotoxic/suppressor T cells, macrophages, and a high percentage of NK precursor cells. Human TIL cytolytic activity is also tumor-specific. 8,21,29,32,51,52,54) However, the cytotox icity of human TILs in vitro is not a good predictor of potential to cause in vivo tumor regression. In vivo TILs have exceptionally suppressed functions, and this effect presumably prevents the generation of an efficient anti-tumor response. Thus, the over all capacity of TILs to affect tumor growth must be considered in the context of both the properties of the lymphocyte population and the capacity of the tumor to inhibit lymphocyte proliferation and its effector functions.3,'°'3,'a) Several investigators have attempted to define the immunogenicity of brain tumors by measuring their growth at subcutaneous sites in nude mice. Tzeng 
